Gilead names new CSO, CMO as Bischofberger departs

Gilead Sciences Inc. (NASDAQ:GILD) said Norbert Bischofberger will step down as EVP of R&D and CSO at the end of April. EVP of Clinical Research John McHutchison will become CSO and lead Gilead's R&D organization.

The company also named EVP of Clinical R&D Andrew Cheng as its next CMO, effective next month...